PMID- 34523731
OWN - NLM
STAT- MEDLINE
DCOM- 20220308
LR  - 20220308
IS  - 1440-0960 (Electronic)
IS  - 0004-8380 (Linking)
VI  - 62
IP  - 4
DP  - 2021 Nov
TI  - Association study of transition of laboratory marker levels and transition of 
      disease activity of atopic dermatitis patients treated with dupilumab.
PG  - e504-e509
LID - 10.1111/ajd.13719 [doi]
AB  - BACKGROUND: Dupilumab, a fully human monoclonal antibody that blocks signalling 
      pathways of interleukin (IL)-4 and IL-13, is effective in treating patients with 
      atopic dermatitis (AD). We previously showed that transitions of serum thymus and 
      activation-regulated chemokine (TARC) levels and eosinophil numbers were strongly 
      associated with that of AD activity and that the transitions of serum lactate 
      dehydrogenase (LDH) and immunoglobulin E (IgE) levels were weakly and not 
      associated with that of AD activity, respectively, in patients treated without 
      dupilumab. OBJECTIVES: The purpose of this study was to elucidate whether the 
      association of the transition of laboratory marker levels and transition of 
      disease activity in dupilumab-treated AD patients (present study) was different 
      from that in patients who are not treated with dupilumab (previous study). 
      METHODS: Sixty AD outpatients treated with dupilumab were included in this study. 
      Associations between the transition of the eczema area and severity index (EASI) 
      score and those of above-mentioned laboratory marker levels were evaluated using 
      a mixed effects model of EASI as the response variable, laboratory markers as 
      fixed effects and patients as random effects. RESULTS: The transitions of serum 
      TARC and LDH levels were associated strongly with that of AD activity, but the 
      transitions of serum IgE level and eosinophil numbers were associated with that 
      of AD activity intermediately and weakly, respectively. CONCLUSIONS: Laboratory 
      markers are useful for evaluating the effects of treatments for AD, but the 
      meaning of each laboratory marker depends on the drugs used for treatment.
CI  - (c) 2021 The Australasian College of Dermatologists.
FAU - Mizuno, Maki
AU  - Mizuno M
AD  - Department of Dermatology, Nippon Medical School, Tokyo, Japan.
FAU - Horiguchi, Go
AU  - Horiguchi G
AD  - Department of Biostatistics, Graduate School of Medical Science, Kyoto 
      Prefectural University of Medicine, Kyoto, Japan.
FAU - Teramukai, Satoshi
AU  - Teramukai S
AD  - Department of Biostatistics, Graduate School of Medical Science, Kyoto 
      Prefectural University of Medicine, Kyoto, Japan.
FAU - Ichiyama, Susumu
AU  - Ichiyama S
AD  - Department of Dermatology, Nippon Medical School, Tokyo, Japan.
FAU - Ito, Michiko
AU  - Ito M
AD  - Department of Dermatology, Nippon Medical School, Tokyo, Japan.
FAU - Hoashi, Toshihiko
AU  - Hoashi T
AD  - Department of Dermatology, Nippon Medical School, Tokyo, Japan.
FAU - Kanda, Naoko
AU  - Kanda N
AUID- ORCID: 0000-0003-4389-2312
AD  - Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Chiba, 
      Japan.
FAU - Saeki, Hidehisa
AU  - Saeki H
AUID- ORCID: 0000-0002-1095-0355
AD  - Department of Dermatology, Nippon Medical School, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210915
PL  - Australia
TA  - Australas J Dermatol
JT  - The Australasian journal of dermatology
JID - 0135232
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biomarkers)
RN  - 0 (CCL17 protein, human)
RN  - 0 (Chemokine CCL17)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 420K487FSG (dupilumab)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Biomarkers/blood
MH  - Blood Cell Count
MH  - Chemokine CCL17/*blood
MH  - Cohort Studies
MH  - Dermatitis, Atopic/*blood/*drug therapy/pathology
MH  - Eosinophils
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/*blood
MH  - L-Lactate Dehydrogenase/*blood
MH  - Male
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Treatment Outcome
OTO - NOTNLM
OT  - association study
OT  - atopic dermatitis
OT  - disease activity
OT  - dupilumab
OT  - laboratory marker
EDAT- 2021/09/16 06:00
MHDA- 2022/03/09 06:00
CRDT- 2021/09/15 09:05
PHST- 2021/08/13 00:00 [revised]
PHST- 2021/07/26 00:00 [received]
PHST- 2021/08/15 00:00 [accepted]
PHST- 2021/09/16 06:00 [pubmed]
PHST- 2022/03/09 06:00 [medline]
PHST- 2021/09/15 09:05 [entrez]
AID - 10.1111/ajd.13719 [doi]
PST - ppublish
SO  - Australas J Dermatol. 2021 Nov;62(4):e504-e509. doi: 10.1111/ajd.13719. Epub 2021 
      Sep 15.